. 2009 Mar; 21(2):215-23.
doi: 10.1016/j.coi.2009.02.009.

The promise and potential pitfalls of chimeric antigen receptors

Michel Sadelain 1 Renier Brentjens  Isabelle Rivière  
  • PMID: 19327974
  •     120 References
  •     212 citations


One important purpose of T cell engineering is to generate tumor-targeted T cells through the genetic transfer of antigen-specific receptors, which consist of either physiological, MHC-restricted T cell receptors (TCRs) or non MHC-restricted chimeric antigen receptors (CARs). CARs combine antigen-specificity and T cell activating properties in a single fusion molecule. First generation CARs, which included as their signaling domain the cytoplasmic region of the CD3zeta or Fc receptor gamma chain, effectively redirected T cell cytotoxicity but failed to enable T cell proliferation and survival upon repeated antigen exposure. Receptors encompassing both CD28 and CD3zeta are the prototypes for second generation CARs, which are now rapidly expanding to a diverse array of receptors with different functional properties. First generation CARs have been tested in phase I clinical studies in patients with ovarian cancer, renal cancer, lymphoma, and neuroblastoma, where they have induced modest responses. Second generation CARs, which are just now entering the clinical arena in the B cell malignancies and other cancers, will provide a more significant test for this approach. If the immunogenicity of CARs can be averted, the versatility of their design and HLA-independent antigen recognition will make CARs tools of choice for T cell engineering for the development of targeted cancer immunotherapies.

Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
Martin A Pule, Barbara Savoldo, +13 authors, Malcolm K Brenner.
Nat Med, 2008 Nov 04; 14(11). PMID: 18978797    Free PMC article.
Highly Cited.
Gene-modified T cells for adoptive immunotherapy of renal cell cancer maintain transgene-specific immune functions in vivo.
Cor H J Lamers, Sabine C L Langeveld, +3 authors, Jan Willem Gratama.
Cancer Immunol Immunother, 2007 May 05; 56(12). PMID: 17479266
Dynamics of tumor cell killing by human T lymphocytes armed with an anti-carcinoembryonic antigen chimeric immunoglobulin T-cell receptor.
E J Beecham, S Ortiz-Pujols, R P Junghans.
J Immunother, 2000 Jun 06; 23(3). PMID: 10838662
Integrated src kinase and costimulatory activity enhances signal transduction through single-chain chimeric receptors in T lymphocytes.
T L Geiger, P Nguyen, D Leitenberg, R A Flavell.
Blood, 2001 Oct 06; 98(8). PMID: 11588032
Single-chain antigen recognition receptors that costimulate potent rejection of established experimental tumors.
Nicole M Haynes, Joseph A Trapani, +6 authors, Phillip K Darcy.
Blood, 2002 Oct 18; 100(9). PMID: 12384413
Dual-specific T cells combine proliferation and antitumor activity.
Michael H Kershaw, Jennifer A Westwood, Patrick Hwu.
Nat Biotechnol, 2002 Nov 05; 20(12). PMID: 12415288
Redirected activity of human antitumor chimeric immune receptors is governed by antigen and receptor expression levels and affinity of interaction.
Fabio Turatti, Mariangela Figini, +5 authors, Delia Mezzanzanica.
J Immunother, 2007 Sep 26; 30(7). PMID: 17893561
The combination of cyclophosphamide and human T cells genetically engineered to target CD19 can eradicate established B-cell lymphoma.
Eleanor J Cheadle, David E Gilham, Robert E Hawkins.
Br J Haematol, 2008 May 15; 142(1). PMID: 18477047
Targeting tumours with genetically enhanced T lymphocytes.
Michel Sadelain, Isabelle Rivière, Renier Brentjens.
Nat Rev Cancer, 2003 Jan 02; 3(1). PMID: 12509765
Highly Cited. Review.
Cellular immunotherapy for follicular lymphoma using genetically modified CD20-specific CD8+ cytotoxic T lymphocytes.
Jinjuan Wang, Oliver W Press, +7 authors, Michael C Jensen.
Mol Ther, 2004 Apr 20; 9(4). PMID: 15093188
Rejection of syngeneic colon carcinoma by CTLs expressing single-chain antibody receptors codelivering CD28 costimulation.
Nicole M Haynes, Joseph A Trapani, +6 authors, Phillip K Darcy.
J Immunol, 2002 Nov 08; 169(10). PMID: 12421958
Cytolysis of tumor cells expressing the Neu/erbB-2, erbB-3, and erbB-4 receptors by genetically targeted naive T lymphocytes.
U Altenschmidt, R Kahl, +4 authors, B Groner.
Clin Cancer Res, 1996 Jun 01; 2(6). PMID: 9816261
A functional role for CD28 costimulation in tumor recognition by single-chain receptor-modified T cells.
Maria Moeller, Nicole M Haynes, +8 authors, Phillip K Darcy.
Cancer Gene Ther, 2004 Apr 03; 11(5). PMID: 15060573
Targeting of T lymphocytes to melanoma cells through chimeric anti-GD3 immunoglobulin T-cell receptors.
C O Yun, K F Nolan, +2 authors, R P Junghans.
Neoplasia, 2001 Feb 24; 2(5). PMID: 11191112    Free PMC article.
Specific targeting of EGP-2+ tumor cells by primary lymphocytes modified with chimeric T cell receptors.
L Ren-Heidenreich, G T Hayman, K T Trevor.
Hum Gene Ther, 2000 Jan 26; 11(1). PMID: 10646635
Functional balance between T cell chimeric receptor density and tumor associated antigen density: CTL mediated cytolysis and lymphokine production.
M E Weijtens, E H Hart, R L Bolhuis.
Gene Ther, 2000 Feb 19; 7(1). PMID: 10680014
Antigen-specific cytolysis by neutrophils and NK cells expressing chimeric immune receptors bearing zeta or gamma signaling domains.
M R Roberts, K S Cooke, +7 authors, M H Finer.
J Immunol, 1998 Jul 01; 161(1). PMID: 9647246
Tumor immunotherapy across MHC barriers using allogeneic T-cell precursors.
Johannes L Zakrzewski, David Suh, +17 authors, Marcel R M van den Brink.
Nat Biotechnol, 2008 Apr 01; 26(4). PMID: 18376399    Free PMC article.
CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
Claudia M Kowolik, Max S Topp, +7 authors, Laurence J N Cooper.
Cancer Res, 2006 Nov 17; 66(22). PMID: 17108138
Highly Cited.
Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kanwarpal S Kahlon, Christine Brown, +3 authors, Michael C Jensen.
Cancer Res, 2004 Dec 18; 64(24). PMID: 15604287
Highly Cited.
Anti-prostate specific membrane antigen designer T cells for prostate cancer therapy.
Qiangzhong Ma, Mazin Safar, +3 authors, Richard P Junghans.
Prostate, 2004 Aug 03; 61(1). PMID: 15287090
Recognition of human colon cancer by T cells transduced with a chimeric receptor gene.
T Daly, R E Royal, +6 authors, P Hwu.
Cancer Gene Ther, 2000 Apr 19; 7(2). PMID: 10770638
Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.
Anna Kruschinski, Andreas Moosmann, +7 authors, Jehad Charo.
Proc Natl Acad Sci U S A, 2008 Nov 07; 105(45). PMID: 18987320    Free PMC article.
T cell-encoded CD80 and 4-1BBL induce auto- and transcostimulation, resulting in potent tumor rejection.
Matthias T Stephan, Vladimir Ponomarev, +4 authors, Michel Sadelain.
Nat Med, 2007 Nov 21; 13(12). PMID: 18026115
Highly Cited.
In vivo cervical cancer growth inhibition by genetically engineered cytotoxic T cells.
Peter Dall, Isabell Herrmann, +4 authors, Dieter Niederacher.
Cancer Immunol Immunother, 2005 Feb 05; 54(1). PMID: 15693139
Molecular mechanisms of HLA class I antigen abnormalities following viral infection and transformation.
Barbara Seliger, Ulrike Ritz, Soldano Ferrone.
Int J Cancer, 2005 Jul 09; 118(1). PMID: 16003759
Expression of a CD20-specific chimeric antigen receptor enhances cytotoxic activity of NK cells and overcomes NK-resistance of lymphoma and leukemia cells.
Tina Müller, Christoph Uherek, +5 authors, Winfried S Wels.
Cancer Immunol Immunother, 2007 Aug 25; 57(3). PMID: 17717662
Generation of gene-modified T cells reactive against the angiogenic kinase insert domain-containing receptor (KDR) found on tumor vasculature.
M H Kershaw, J A Westwood, +3 authors, P Hwu.
Hum Gene Ther, 2000 Dec 19; 11(18). PMID: 11119416
Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.
Claudia Rossig, Catherine M Bollard, +2 authors, Malcolm K Brenner.
Blood, 2002 Mar 06; 99(6). PMID: 11877273
Display, engineering, and applications of antigen-specific T cell receptors.
Sarah A Richman, David M Kranz.
Biomol Eng, 2007 Apr 06; 24(4). PMID: 17409021
Immunotherapy with chimeric NKG2D receptors leads to long-term tumor-free survival and development of host antitumor immunity in murine ovarian cancer.
Amorette Barber, Tong Zhang, Charles L Sentman.
J Immunol, 2007 Dec 22; 180(1). PMID: 18097006
T cells engrafted with a recombinant anti-CD30 receptor target autologous CD30(+) cutaneous lymphoma cells.
A Hombach, J M Muche, +5 authors, H Abken.
Gene Ther, 2001 Jun 26; 8(11). PMID: 11423937
The role of extracellular spacer regions in the optimal design of chimeric immune receptors: evaluation of four different scFvs and antigens.
Ryan D Guest, Robert E Hawkins, +10 authors, David E Gilham.
J Immunother, 2005 Apr 20; 28(3). PMID: 15838376
Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.
Tong Zhang, Amorette Barber, Charles L Sentman.
Cancer Res, 2007 Nov 17; 67(22). PMID: 18006849
Eradication of systemic B-cell tumors by genetically targeted human T lymphocytes co-stimulated by CD80 and interleukin-15.
Renier J Brentjens, Jean-Baptiste Latouche, +8 authors, Michel Sadelain.
Nat Med, 2003 Feb 13; 9(3). PMID: 12579196
Highly Cited.
Single chain Ig/gamma gene-redirected human T lymphocytes produce cytokines, specifically lyse tumor cells, and recycle lytic capacity.
M E Weijtens, R A Willemsen, +2 authors, R L Bolhuis.
J Immunol, 1996 Jul 15; 157(2). PMID: 8752936
Rhabdomyosarcoma lysis by T cells expressing a human autoantibody-based chimeric receptor targeting the fetal acetylcholine receptor.
Stefan Gattenlöhner, Alexander Marx, +8 authors, Claudia Rossig.
Cancer Res, 2006 Jan 07; 66(1). PMID: 16397210
Anti-Tumor CC49-zeta CD4 T cells possess both cytolytic and helper functions.
S D Patel, Y Ge, M Moskalenko, J G McArthur.
J Immunother, 2001 Feb 24; 23(6). PMID: 11186154
Targeted elimination of prostate cancer by genetically directed human T lymphocytes.
Terence P F Gade, Waleed Hassen, +16 authors, Michel Sadelain.
Cancer Res, 2005 Oct 06; 65(19). PMID: 16204083
A T cell-independent antitumor response in mice with bone marrow cells retrovirally transduced with an antibody/Fc-gamma chain chimeric receptor gene recognizing a human ovarian cancer antigen.
G Wang, R K Chopra, +3 authors, P Hwu.
Nat Med, 1998 Feb 14; 4(2). PMID: 9461189
Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRzeta /CD28 receptor.
John Maher, Renier J Brentjens, +2 authors, Michel Sadelain.
Nat Biotechnol, 2001 Dec 26; 20(1). PMID: 11753365
Highly Cited.
Adoptive cell transfer: a clinical path to effective cancer immunotherapy.
Steven A Rosenberg, Nicholas P Restifo, +2 authors, Mark E Dudley.
Nat Rev Cancer, 2008 Mar 21; 8(4). PMID: 18354418    Free PMC article.
Highly Cited. Review.
Harnessing endogenous miR-181a to segregate transgenic antigen receptor expression in developing versus post-thymic T cells in murine hematopoietic chimeras.
Eirini P Papapetrou, Damian Kovalovsky, +2 authors, Michel Sadelain.
J Clin Invest, 2008 Nov 27; 119(1). PMID: 19033646    Free PMC article.
Comparison of the TCR zeta-chain with the FcR gamma-chain in chimeric TCR constructs for T cell activation and apoptosis.
Lifen Ren-Heidenreich, Ryan Mordini, +2 authors, Ann LeFever.
Cancer Immunol Immunother, 2002 Aug 31; 51(8). PMID: 12202902
Adoptive immunotherapy for indolent non-Hodgkin lymphoma and mantle cell lymphoma using genetically modified autologous CD20-specific T cells.
Brian G Till, Michael C Jensen, +13 authors, Oliver W Press.
Blood, 2008 May 30; 112(6). PMID: 18509084    Free PMC article.
Highly Cited.
Characterization of in vitro migratory properties of anti-CD19 chimeric receptor-redirected CIK cells for their potential use in B-ALL immunotherapy.
Virna Marin, Erica Dander, +4 authors, Giovanna D'Amico.
Exp Hematol, 2006 Aug 31; 34(9). PMID: 16939815
Anti-tumor activity of human T cells expressing the CC49-zeta chimeric immune receptor.
R P McGuinness, Y Ge, +6 authors, J G McArthur.
Hum Gene Ther, 1999 Feb 18; 10(2). PMID: 10022542
Generation and targeting of human tumor-specific Tc1 and Th1 cells transduced with a lentivirus containing a chimeric immunoglobulin T-cell receptor.
Hiroshi Gyobu, Takemasa Tsuji, +8 authors, Takashi Nishimura.
Cancer Res, 2004 Feb 20; 64(4). PMID: 14973062
The cytoplasmic domain of the T cell receptor zeta chain is sufficient to couple to receptor-associated signal transduction pathways.
B A Irving, A Weiss.
Cell, 1991 Mar 08; 64(5). PMID: 1705867
Highly Cited.
Enhancement of the anti-leukemic activity of cytokine induced killer cells with an anti-CD19 chimeric receptor delivering a 4-1BB-zeta activating signal.
Virna Marin, Harumi Kakuda, +4 authors, Giovanna D'Amico.
Exp Hematol, 2007 Jul 28; 35(9). PMID: 17656004
Molecular mechanisms of MHC class I abnormalities and APM components in human tumors.
Barbara Seliger.
Cancer Immunol Immunother, 2008 Apr 15; 57(11). PMID: 18408926
Ligand-mediated cytolysis of tumor cells: use of heregulin-zeta chimeras to redirect cytotoxic T lymphocytes.
A Muniappan, B Banapour, J Lebkowski, S Talib.
Cancer Gene Ther, 2000 Mar 04; 7(1). PMID: 10678365
Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen.
M C Gong, J B Latouche, +3 authors, M Sadelain.
Neoplasia, 2000 Aug 10; 1(2). PMID: 10933046    Free PMC article.
Relationship between CD8-dependent antigen recognition, T cell functional avidity, and tumor cell recognition.
Tamson V Moore, Gretchen E Lyons, +6 authors, Michael I Nishimura.
Cancer Immunol Immunother, 2008 Oct 07; 58(5). PMID: 18836717    Free PMC article.
Imaging immune response in vivo: cytolytic action of genetically altered T cells directed to glioblastoma multiforme.
Jelena Lazovic, Michael C Jensen, +3 authors, Russell E Jacobs.
Clin Cancer Res, 2008 Jun 19; 14(12). PMID: 18559603    Free PMC article.
Adoptive transfer of in vitro-targeted, activated T lymphocytes results in total tumor regression.
U Altenschmidt, E Klundt, B Groner.
J Immunol, 1998 Apr 21; 159(11). PMID: 9548491
Adoptive transfer of T cells modified with a humanized chimeric receptor gene inhibits growth of Lewis-Y-expressing tumors in mice.
Jennifer A Westwood, Mark J Smyth, +10 authors, Michael H Kershaw.
Proc Natl Acad Sci U S A, 2005 Dec 21; 102(52). PMID: 16365285    Free PMC article.
Antigen-dependent CD28 signaling selectively enhances survival and proliferation in genetically modified activated human primary T lymphocytes.
A Krause, H F Guo, +3 authors, M Sadelain.
J Exp Med, 1998 Aug 26; 188(4). PMID: 9705944    Free PMC article.
Antitumor activity of dual-specific T cells and influenza virus.
A Murphy, J A Westwood, +7 authors, M H Kershaw.
Cancer Gene Ther, 2007 Mar 03; 14(5). PMID: 17332777
Addition of the CD28 signaling domain to chimeric T-cell receptors enhances chimeric T-cell resistance to T regulatory cells.
A Loskog, V Giandomenico, +3 authors, M K Brenner.
Leukemia, 2006 Aug 26; 20(10). PMID: 16932339
Adoptive immunotherapy for cancer: building on success.
Luca Gattinoni, Daniel J Powell, Steven A Rosenberg, Nicholas P Restifo.
Nat Rev Immunol, 2006 Apr 20; 6(5). PMID: 16622476    Free PMC article.
Highly Cited. Review.
Medulloblastomas expressing IL13Ralpha2 are targets for IL13-zetakine+ cytolytic T cells.
Michael J Stastny, Christine E Brown, Christopher Ruel, Michael C Jensen.
J Pediatr Hematol Oncol, 2007 Oct 09; 29(10). PMID: 17921847
Antigen-specific targeting of CD8+ T cells with receptor-modified T lymphocytes.
P Nguyen, T L Geiger.
Gene Ther, 2003 Mar 21; 10(7). PMID: 12646865
In vivo antitumor activity of T cells redirected with chimeric antibody/T-cell receptor genes.
P Hwu, J C Yang, +4 authors, S A Rosenberg.
Cancer Res, 1995 Aug 01; 55(15). PMID: 7614473
T cell retargeting with MHC class I-restricted antibodies: the CD28 costimulatory domain enhances antigen-specific cytotoxicity and cytokine production.
Ralph A Willemsen, Cees Ronteltap, +2 authors, Reinder L H Bolhuis.
J Immunol, 2005 Jun 10; 174(12). PMID: 15944290
Engineered CD20-specific primary human cytotoxic T lymphocytes for targeting B-cell malignancy.
M C Jensen, L J N Cooper, +2 authors, A Raubitschek.
Cytotherapy, 2003 May 15; 5(2). PMID: 12745575
Activation of resting human primary T cells with chimeric receptors: costimulation from CD28, inducible costimulator, CD134, and CD137 in series with signals from the TCR zeta chain.
Helene M Finney, Arne N Akbar, Alastair D G Lawson.
J Immunol, 2003 Dec 23; 172(1). PMID: 14688315
Highly Cited.
Immunotherapy of lymphomas with T cells modified by anti-CD20 scFv/CD28/CD3zeta recombinant gene.
Kang Yu, Yongxian Hu, +5 authors, Daming Shan.
Leuk Lymphoma, 2008 May 03; 49(7). PMID: 18452062
Sequence requirements for induction of cytolysis by the T cell antigen/Fc receptor zeta chain.
C Romeo, M Amiot, B Seed.
Cell, 1992 Mar 06; 68(5). PMID: 1547489
Highly Cited.
Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates.
Carolina Berger, Michael C Jensen, +3 authors, Stanley R Riddell.
J Clin Invest, 2007 Dec 07; 118(1). PMID: 18060041    Free PMC article.
Highly Cited.
Chimeric receptors with 4-1BB signaling capacity provoke potent cytotoxicity against acute lymphoblastic leukemia.
C Imai, K Mihara, +4 authors, D Campana.
Leukemia, 2004 Feb 13; 18(4). PMID: 14961035
Highly Cited.
Genetic modification of primary natural killer cells overcomes inhibitory signals and induces specific killing of leukemic cells.
Chihaya Imai, Shotaro Iwamoto, Dario Campana.
Blood, 2005 Mar 10; 106(1). PMID: 15755898    Free PMC article.
Highly Cited.
In vivo tracking of genetically engineered, anti-HER2/neu directed natural killer cells to HER2/neu positive mammary tumors with magnetic resonance imaging.
Heike E Daldrup-Link, Reinhardt Meier, +8 authors, Ernst J Rummeny.
Eur Radiol, 2004 Dec 24; 15(1). PMID: 15616814
T-cell activation by recombinant receptors: CD28 costimulation is required for interleukin 2 secretion and receptor-mediated T-cell proliferation but does not affect receptor-mediated target cell lysis.
A Hombach, D Sent, +5 authors, H Abken.
Cancer Res, 2001 Mar 31; 61(5). PMID: 11280755
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells.
Martin A Pulè, Karin C Straathof, +3 authors, Malcolm K Brenner.
Mol Ther, 2005 Jun 28; 12(5). PMID: 15979412
Highly Cited.
Redirecting specificity of T-cell populations for CD19 using the Sleeping Beauty system.
Harjeet Singh, Pallavi R Manuri, +8 authors, Laurence J N Cooper.
Cancer Res, 2008 Apr 17; 68(8). PMID: 18413766    Free PMC article.
Highly Cited.
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cells.
Juan Vera, Barbara Savoldo, +8 authors, Gianpietro Dotti.
Blood, 2006 Aug 24; 108(12). PMID: 16926291    Free PMC article.
Highly Cited.
The T-body approach: potential for cancer immunotherapy.
Z Eshhar, N Bach, +4 authors, D G Schindler.
Springer Semin Immunopathol, 1996 Jan 01; 18(2). PMID: 8908700
Optimizing adoptive polyclonal T cell immunotherapy of lymphomas, using a chimeric T cell receptor possessing CD28 and CD137 costimulatory domains.
Jinjuan Wang, Michael Jensen, +11 authors, Oliver W Press.
Hum Gene Ther, 2007 Aug 10; 18(8). PMID: 17685852
Antitumor activity of cytotoxic T lymphocytes engineered to target vascular endothelial growth factor receptors.
Thomas M J Niederman, Zoher Ghogawala, +3 authors, Richard C Mulligan.
Proc Natl Acad Sci U S A, 2002 May 09; 99(10). PMID: 11997459    Free PMC article.
Expansion and characterization of T cells transduced with a chimeric receptor against ovarian cancer.
L L Parker, M T Do, +4 authors, P Hwu.
Hum Gene Ther, 2000 Nov 30; 11(17). PMID: 11096442
Antitumor activity of chimeric immunoreceptor gene-modified Tc1 and Th1 cells against autologous carcinoembryonic antigen-expressing colon cancer cells.
Takeshi Sasaki, Hiroaki Ikeda, +7 authors, Takashi Nishimura.
Cancer Sci, 2006 Jul 22; 97(9). PMID: 16856879
An entirely humanized CD3 zeta-chain signaling receptor that directs peripheral blood t cells to specific lysis of carcinoembryonic antigen-positive tumor cells.
A Hombach, C Schneider, +7 authors, H Abken.
Int J Cancer, 2000 Aug 30; 88(1). PMID: 10962448
Bypassing immunization: optimized design of "designer T cells" against carcinoembryonic antigen (CEA)-expressing tumors, and lack of suppression by soluble CEA.
K F Nolan, C O Yun, +4 authors, R P Junghans.
Clin Cancer Res, 2000 Jan 13; 5(12). PMID: 10632322
Transgene-enforced co-stimulation of CD4+ T cells leads to enhanced and sustained anti-tumor effector functioning.
L Chang, W C Chang, +3 authors, M C Jensen.
Cytotherapy, 2007 Oct 06; 9(8). PMID: 17917884
Retargeting of natural killer-cell cytolytic activity to ErbB2-expressing cancer cells results in efficient and selective tumor cell destruction.
Christoph Uherek, Torsten Tonn, +4 authors, Winfried Wels.
Blood, 2002 Aug 01; 100(4). PMID: 12149207
Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma.
Julie R Park, David L Digiusto, +8 authors, Michael C Jensen.
Mol Ther, 2007 Feb 15; 15(4). PMID: 17299405
Highly Cited.
Protection from lethal infection by adoptive transfer of CD8 T cells genetically engineered to express virus-specific innate immune receptor.
Koho Iizuka, Chigusa Nakajima, +5 authors, Osami Kanagawa.
J Immunol, 2007 Jul 10; 179(2). PMID: 17617605
Manufacturing validation of biologically functional T cells targeted to CD19 antigen for autologous adoptive cell therapy.
Daniel Hollyman, Jolanta Stefanski, +10 authors, Isabelle Rivière.
J Immunother, 2009 Feb 25; 32(2). PMID: 19238016    Free PMC article.
Immunotherapy of cancer using systemically delivered gene-modified human T lymphocytes.
Michele W L Teng, Michael H Kershaw, +2 authors, Phillip K Darcy.
Hum Gene Ther, 2004 Jul 10; 15(7). PMID: 15242530
Monitoring the efficacy of adoptively transferred prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging.
Konstantin Dobrenkov, Malgorzata Olszewska, +7 authors, Vladimir Ponomarev.
J Nucl Med, 2008 Jun 17; 49(7). PMID: 18552144    Free PMC article.
Gene-engineered varicella-zoster virus reactive CD4+ cytotoxic T cells exert tumor-specific effector function.
Silke Landmeier, Bianca Altvater, +5 authors, Claudia Rossig.
Cancer Res, 2007 Sep 07; 67(17). PMID: 17804749
Redirected perforin-dependent lysis of colon carcinoma by ex vivo genetically engineered CTL.
P K Darcy, N M Haynes, +4 authors, M J Smyth.
J Immunol, 2000 Mar 22; 164(7). PMID: 10725729
Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the gamma or zeta subunits of the immunoglobulin and T-cell receptors.
Z Eshhar, T Waks, G Gross, D G Schindler.
Proc Natl Acad Sci U S A, 1993 Jan 15; 90(2). PMID: 8421711    Free PMC article.
Highly Cited.
Adoptive transfer of gene-modified primary NK cells can specifically inhibit tumor progression in vivo.
Hollie J Pegram, Jacob T Jackson, +2 authors, Phillip K Darcy.
J Immunol, 2008 Aug 21; 181(5). PMID: 18714017
Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
Barbara Savoldo, Cliona M Rooney, +7 authors, Gianpietro Dotti.
Blood, 2007 May 18; 110(7). PMID: 17507664    Free PMC article.
Coupling CD28 co-stimulation to immunoglobulin T-cell receptor molecules: the dynamics of T-cell proliferation and death.
E J Beecham, Q Ma, R Ripley, R P Junghans.
J Immunother, 2001 Feb 24; 23(6). PMID: 11186151
Immuno-gene therapy of established prostate tumors using chimeric receptor-redirected human lymphocytes.
Jehonathan H Pinthus, Tova Waks, +5 authors, Zelig Eshhar.
Cancer Res, 2003 May 17; 63(10). PMID: 12750268
CD4+ T cells engrafted with a recombinant immunoreceptor efficiently lyse target cells in a MHC antigen- and Fas-independent fashion.
A Hombach, C Heuser, +4 authors, H Abken.
J Immunol, 2001 Jul 07; 167(2). PMID: 11441120
Adoptive transfer of T-cell precursors enhances T-cell reconstitution after allogeneic hematopoietic stem cell transplantation.
Johannes L Zakrzewski, Adam A Kochman, +20 authors, Marcel R M van den Brink.
Nat Med, 2006 Aug 29; 12(9). PMID: 16936725
Genetic engineering of cytolytic T lymphocytes for adoptive T-cell therapy of neuroblastoma.
Sergio Gonzalez, Araceli Naranjo, +3 authors, Michael C Jensen.
J Gene Med, 2004 Jun 02; 6(6). PMID: 15170741
Chimeric NKG2D receptor-bearing T cells as immunotherapy for ovarian cancer.
Amorette Barber, Tong Zhang, +3 authors, Charles L Sentman.
Cancer Res, 2007 May 19; 67(10). PMID: 17510432
Treatment of metastatic renal cell carcinoma with autologous T-lymphocytes genetically retargeted against carbonic anhydrase IX: first clinical experience.
Cor H J Lamers, Stefan Sleijfer, +6 authors, Egbert Oosterwijk.
J Clin Oncol, 2006 May 02; 24(13). PMID: 16648493
Highly Cited.
Tumor-specific T cell activation by recombinant immunoreceptors: CD3 zeta signaling and CD28 costimulation are simultaneously required for efficient IL-2 secretion and can be integrated into one combined CD28/CD3 zeta signaling receptor molecule.
A Hombach, A Wieczarkowiecz, +5 authors, H Abken.
J Immunol, 2001 Nov 21; 167(11). PMID: 11714771
Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.
William Y Ho, Joseph N Blattman, +2 authors, Philip D Greenberg.
Cancer Cell, 2003 Jun 05; 3(5). PMID: 12781360
Redirecting mouse CTL against colon carcinoma: superior signaling efficacy of single-chain variable domain chimeras containing TCR-zeta vs Fc epsilon RI-gamma.
N M Haynes, M B Snook, +4 authors, P K Darcy.
J Immunol, 2000 Dec 21; 166(1). PMID: 11123291
Antigen sensitivity of CD22-specific chimeric TCR is modulated by target epitope distance from the cell membrane.
Scott E James, Philip D Greenberg, +6 authors, Oliver W Press.
J Immunol, 2008 May 06; 180(10). PMID: 18453625    Free PMC article.
Combination of vaccination and chimeric receptor expressing T cells provides improved active therapy of tumors.
Hui-Rong Jiang, David E Gilham, +3 authors, Peter L Stern.
J Immunol, 2006 Sep 20; 177(7). PMID: 16982863
A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer.
Michael H Kershaw, Jennifer A Westwood, +11 authors, Patrick Hwu.
Clin Cancer Res, 2006 Oct 26; 12(20 Pt 1). PMID: 17062687    Free PMC article.
Highly Cited.
Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
Laurence J N Cooper, Zaid Al-Kadhimi, +8 authors, Michael C Jensen.
Blood, 2004 Oct 28; 105(4). PMID: 15507526
Chimeric scFv/gamma receptor-mediated T-cell lysis of tumor cells is coregulated by adhesion and accessory molecules.
M E Weijtens, R A Willemsen, B A van Krimpen, R L Bolhuis.
Int J Cancer, 1998 Jul 03; 77(2). PMID: 9650549
Transfer of chimeric receptor gene made of variable regions of tumor-specific antibody confers anticarbohydrate specificity on T cells.
D Mezzanzanica, S Canevari, +5 authors, Z Eshhar.
Cancer Gene Ther, 1999 Jan 23; 5(6). PMID: 9917095
Adoptive transfer of chimeric FcepsilonRI gene-modified human T cells for cancer immunotherapy.
Michele W L Teng, Michael H Kershaw, +2 authors, Phillip K Darcy.
Hum Gene Ther, 2006 Oct 21; 17(11). PMID: 17052145
Sleeping Beauty transposon-mediated engineering of human primary T cells for therapy of CD19+ lymphoid malignancies.
Xin Huang, Hongfeng Guo, +13 authors, Xianzheng Zhou.
Mol Ther, 2008 Jan 30; 16(3). PMID: 18227839    Free PMC article.
Adoptive transfer of gene-engineered CD4+ helper T cells induces potent primary and secondary tumor rejection.
Maria Moeller, Nicole M Haynes, +8 authors, Phillip K Darcy.
Blood, 2005 Jul 21; 106(9). PMID: 16030195
Retargeting of human T cells to tumor-associated MUC1: the evolution of a chimeric antigen receptor.
Scott Wilkie, Gianfranco Picco, +8 authors, John Maher.
J Immunol, 2008 Mar 21; 180(7). PMID: 18354214
Human monocytes expressing a CEA-specific chimeric CD64 receptor specifically target CEA-expressing tumour cells in vitro and in vivo.
A Biglari, T D Southgate, L J Fairbairn, D E Gilham.
Gene Ther, 2006 Jan 07; 13(7). PMID: 16397508
Targeting of tumor cells expressing the prostate stem cell antigen (PSCA) using genetically engineered T-cells.
Agnieszka Morgenroth, Marc Cartellieri, +6 authors, Achim Temme.
Prostate, 2007 May 12; 67(10). PMID: 17492652
Regression of experimental medulloblastoma following transfer of HER2-specific T cells.
Nabil Ahmed, Maheshika Ratnayake, +10 authors, Stephen Gottschalk.
Cancer Res, 2007 Jun 19; 67(12). PMID: 17575166
Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts.
Renier J Brentjens, Elmer Santos, +6 authors, Michel Sadelain.
Clin Cancer Res, 2007 Sep 15; 13(18 Pt 1). PMID: 17855649
Highly Cited.
Adoptive T cell therapy of cancer.
Ton N M Schumacher, Nicholas P Restifo.
Curr Opin Immunol, 2009 Mar 31; 21(2). PMID: 19328668    Free PMC article.
Persuading natural killer cells to eliminate bad B cells.
Laurence J N Cooper.
Clin Cancer Res, 2009 Jul 30; 15(15). PMID: 19638468    Free PMC article.
Cellular therapies in acute lymphoblastic leukemia.
Renier J Brentjens.
Curr Opin Mol Ther, 2009 Aug 04; 11(4). PMID: 19649982    Free PMC article.
Fifteen years of gene therapy based on chimeric antigen receptors: "are we nearly there yet?".
Gianpietro Dotti, Barbara Savoldo, Malcolm Brenner.
Hum Gene Ther, 2009 Aug 26; 20(11). PMID: 19702437    Free PMC article.
Chimeric antigen receptors combining 4-1BB and CD28 signaling domains augment PI3kinase/AKT/Bcl-XL activation and CD8+ T cell-mediated tumor eradication.
Xiao-Song Zhong, Maiko Matsushita, +2 authors, Michel Sadelain.
Mol Ther, 2009 Sep 24; 18(2). PMID: 19773745    Free PMC article.
Highly Cited.
Engineering lymphocyte subsets: tools, trials and tribulations.
Carl H June, Bruce R Blazar, James L Riley.
Nat Rev Immunol, 2009 Oct 28; 9(10). PMID: 19859065    Free PMC article.
Immunotherapy of human cancers using gene modified T lymphocytes.
Juan F Vera, Malcolm K Brenner, Gianpietro Dotti.
Curr Gene Ther, 2009 Oct 29; 9(5). PMID: 19860654    Free PMC article.
Immune-based therapeutics for pediatric cancer.
Christian M Capitini, Crystal L Mackall, Alan S Wayne.
Expert Opin Biol Ther, 2009 Dec 02; 10(2). PMID: 19947897    Free PMC article.
Immunotherapy of childhood cancer: from biologic understanding to clinical application.
Alan S Wayne, Christian M Capitini, Crystal L Mackall.
Curr Opin Pediatr, 2009 Dec 03; 22(1). PMID: 19952749    Free PMC article.
Allogeneic haematopoietic stem cell transplantation: individualized stem cell and immune therapy of cancer.
Robert R Jenq, Marcel R M van den Brink.
Nat Rev Cancer, 2010 Feb 20; 10(3). PMID: 20168320
Mathematical modeling of chimeric TCR triggering predicts the magnitude of target lysis and its impairment by TCR downmodulation.
Scott E James, Philip D Greenberg, +7 authors, Oliver W Press.
J Immunol, 2010 Mar 12; 184(8). PMID: 20220093    Free PMC article.
Antitransgene rejection responses contribute to attenuated persistence of adoptively transferred CD20/CD19-specific chimeric antigen receptor redirected T cells in humans.
Michael C Jensen, Leslie Popplewell, +4 authors, Stephen J Forman.
Biol Blood Marrow Transplant, 2010 Mar 23; 16(9). PMID: 20304086    Free PMC article.
Highly Cited.
Treatment of chronic lymphocytic leukemia with genetically targeted autologous T cells: case report of an unforeseen adverse event in a phase I clinical trial.
Renier Brentjens, Raymond Yeh, +2 authors, Michel Sadelain.
Mol Ther, 2010 Apr 02; 18(4). PMID: 20357779    Free PMC article.
Highly Cited.
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety.
V Hoyos, B Savoldo, +7 authors, G Dotti.
Leukemia, 2010 Apr 30; 24(6). PMID: 20428207    Free PMC article.
Highly Cited.
Redirecting T-cell specificity by introducing a tumor-specific chimeric antigen receptor.
Bipulendu Jena, Gianpietro Dotti, Laurence J N Cooper.
Blood, 2010 May 05; 116(7). PMID: 20439624    Free PMC article.
Highly Cited. Review.
Chimeric antigen receptor-engineered T cells for immunotherapy of cancer.
Marc Cartellieri, Michael Bachmann, +5 authors, Marc Schmitz.
J Biomed Biotechnol, 2010 May 15; 2010. PMID: 20467460    Free PMC article.
Designing customized cell signalling circuits.
Wendell A Lim.
Nat Rev Mol Cell Biol, 2010 May 21; 11(6). PMID: 20485291    Free PMC article.
Highly Cited. Review.
Selective expansion of chimeric antigen receptor-targeted T-cells with potent effector function using interleukin-4.
Scott Wilkie, Sophie E Burbridge, +6 authors, John Maher.
J Biol Chem, 2010 Jun 22; 285(33). PMID: 20562098    Free PMC article.
NCI First International Workshop on The Biology, Prevention and Treatment of Relapse after Allogeneic Hematopoietic Cell Transplantation: report from the committee on prevention of relapse following allogeneic cell transplantation for hematologic malignancies.
Edwin P Alyea, Daniel J DeAngelo, +7 authors, Stan Riddell.
Biol Blood Marrow Transplant, 2010 Jun 29; 16(8). PMID: 20580849    Free PMC article.
Cell-based immunotherapy of prion diseases by adoptive transfer of antigen-loaded dendritic cells or antigen-primed CD(4+) T lymphocytes.
Claude Carnaud, Véronique Bachy.
Prion, 2010 Jul 14; 4(2). PMID: 20622507    Free PMC article.
Successful eradication of established peritoneal ovarian tumors in SCID-Beige mice following adoptive transfer of T cells genetically targeted to the MUC16 antigen.
Alena A Chekmasova, Thapi D Rao, +4 authors, Renier J Brentjens.
Clin Cancer Res, 2010 Jul 16; 16(14). PMID: 20628030    Free PMC article.
Adoptive transfer of syngeneic T cells transduced with a chimeric antigen receptor that recognizes murine CD19 can eradicate lymphoma and normal B cells.
James N Kochenderfer, Zhiya Yu, +2 authors, Steven A Rosenberg.
Blood, 2010 Jul 16; 116(19). PMID: 20631379    Free PMC article.
Highly Cited.
Immunotherapy following hematopoietic stem cell transplantation: potential for synergistic effects.
Myriam N Bouchlaka, Doug Redelman, William J Murphy.
Immunotherapy, 2010 Jul 20; 2(3). PMID: 20635904    Free PMC article.
Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19.
James N Kochenderfer, Wyndham H Wilson, +9 authors, Steven A Rosenberg.
Blood, 2010 Jul 30; 116(20). PMID: 20668228    Free PMC article.
Highly Cited.
Cytokine-induced killer cells for cell therapy of acute myeloid leukemia: improvement of their immune activity by expression of CD33-specific chimeric receptors.
Virna Marin, Irene Pizzitola, +7 authors, Ettore Biagi.
Haematologica, 2010 Aug 18; 95(12). PMID: 20713459    Free PMC article.
Multiple injections of electroporated autologous T cells expressing a chimeric antigen receptor mediate regression of human disseminated tumor.
Yangbing Zhao, Edmund Moon, +9 authors, Carl H June.
Cancer Res, 2010 Oct 12; 70(22). PMID: 20926399    Free PMC article.
Highly Cited.
Immunotherapy for ovarian cancer: what's next?
Lana E Kandalaft, Daniel J Powell, Nathan Singh, George Coukos.
J Clin Oncol, 2010 Nov 17; 29(7). PMID: 21079136    Free PMC article.
Identification and engineering of human variable regions that allow expression of stable single-chain T cell receptors.
David H Aggen, Adam S Chervin, +3 authors, David M Kranz.
Protein Eng Des Sel, 2010 Dec 17; 24(4). PMID: 21159619    Free PMC article.
Meganucleases and other tools for targeted genome engineering: perspectives and challenges for gene therapy.
George Silva, Laurent Poirot, +4 authors, Frédéric Pâques.
Curr Gene Ther, 2010 Dec 25; 11(1). PMID: 21182466    Free PMC article.
Focus on adoptive T cell transfer trials in melanoma.
Liat Hershkovitz, Jacob Schachter, Avraham J Treves, Michal J Besser.
Clin Dev Immunol, 2011 Jan 15; 2010. PMID: 21234353    Free PMC article.
Stem cell-based anti-HIV gene therapy.
Scott G Kitchen, Saki Shimizu, Dong Sung An.
Virology, 2011 Jan 21; 411(2). PMID: 21247612    Free PMC article.
CARs on track in the clinic.
Donald B Kohn, Gianpietro Dotti, +7 authors, Helen E Heslop.
Mol Ther, 2011 Mar 02; 19(3). PMID: 21358705    Free PMC article.
In vitro and in vivo model of a novel immunotherapy approach for chronic lymphocytic leukemia by anti-CD23 chimeric antigen receptor.
Greta Maria Paola Giordano Attianese, Virna Marin, +11 authors, Ettore Biagi.
Blood, 2011 Mar 17; 117(18). PMID: 21406718    Free PMC article.
Ex vivo gene transfer for improved adoptive immunotherapy of cancer.
Minhtran C Ngo, Cliona M Rooney, Jeffrey M Howard, Helen E Heslop.
Hum Mol Genet, 2011 Mar 19; 20(R1). PMID: 21415041    Free PMC article.
Synthetic conversion of a graded receptor signal into a tunable, reversible switch.
Santhosh Palani, Casim A Sarkar.
Mol Syst Biol, 2011 Apr 01; 7. PMID: 21451590    Free PMC article.
NKG2D receptor regulates human effector T-cell cytokine production.
Amorette Barber, Charles L Sentman.
Blood, 2011 Apr 27; 117(24). PMID: 21518928    Free PMC article.
Identification of amino acids that account for long-range interactions in two triosephosphate isomerases from pathogenic trypanosomes.
Itzhel García-Torres, Nallely Cabrera, +4 authors, Ruy Perez-Montfort.
PLoS One, 2011 May 03; 6(4). PMID: 21533154    Free PMC article.
CD28 costimulation improves expansion and persistence of chimeric antigen receptor-modified T cells in lymphoma patients.
Barbara Savoldo, Carlos Almeida Ramos, +13 authors, Gianpietro Dotti.
J Clin Invest, 2011 May 05; 121(5). PMID: 21540550    Free PMC article.
Highly Cited.
Treating cancer with genetically engineered T cells.
Tristen S Park, Steven A Rosenberg, Richard A Morgan.
Trends Biotechnol, 2011 Jun 15; 29(11). PMID: 21663987    Free PMC article.
Chimeric Antigen Receptor Therapy for B-cell Malignancies.
David L Porter, Michael Kalos, +2 authors, Carl June.
J Cancer, 2011 Jul 01; 2. PMID: 21716851    Free PMC article.
Single-chain VαVβ T-cell receptors function without mispairing with endogenous TCR chains.
D H Aggen, A S Chervin, +8 authors, D M Kranz.
Gene Ther, 2011 Jul 15; 19(4). PMID: 21753797    Free PMC article.
PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
Yozo Nakazawa, Leslie E Huye, +7 authors, Cliona M Rooney.
Mol Ther, 2011 Jul 21; 19(12). PMID: 21772253    Free PMC article.
Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.
David L Porter, Bruce L Levine, +2 authors, Carl H June.
N Engl J Med, 2011 Aug 13; 365(8). PMID: 21830940    Free PMC article.
Highly Cited.
T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia.
Michael Kalos, Bruce L Levine, +4 authors, Carl H June.
Sci Transl Med, 2011 Aug 13; 3(95). PMID: 21832238    Free PMC article.
Highly Cited.
Treatment of advanced leukemia in mice with mRNA engineered T cells.
David M Barrett, Yangbing Zhao, +6 authors, Stephan A Grupp.
Hum Gene Ther, 2011 Aug 16; 22(12). PMID: 21838572    Free PMC article.
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias.
Renier J Brentjens, Isabelle Rivière, +24 authors, Michel Sadelain.
Blood, 2011 Aug 19; 118(18). PMID: 21849486    Free PMC article.
Highly Cited.
Combining mTor inhibitors with rapamycin-resistant T cells: a two-pronged approach to tumor elimination.
Leslie E Huye, Yozo Nakazawa, +6 authors, Cliona M Rooney.
Mol Ther, 2011 Sep 01; 19(12). PMID: 21878902    Free PMC article.
Memory T cells from minor histocompatibility antigen-vaccinated and virus-immune donors improve GVL and immune reconstitution.
Ning Li, Catherine Matte-Martone, +8 authors, Warren D Shlomchik.
Blood, 2011 Sep 16; 118(22). PMID: 21917752    Free PMC article.
Antitumor activity and long-term fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma.
Chrystal U Louis, Barbara Savoldo, +14 authors, Malcolm K Brenner.
Blood, 2011 Oct 11; 118(23). PMID: 21984804    Free PMC article.
Highly Cited.
Cellular therapies in acute lymphoblastic leukemia.
Jae H Park, Craig Sauter, Renier Brentjens.
Hematol Oncol Clin North Am, 2011 Nov 19; 25(6). PMID: 22093587    Free PMC article.
Emerging biomedical applications of synthetic biology.
Wilfried Weber, Martin Fussenegger.
Nat Rev Genet, 2011 Nov 30; 13(1). PMID: 22124480    Free PMC article.
Highly Cited. Review.
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells.
James N Kochenderfer, Mark E Dudley, +15 authors, Steven A Rosenberg.
Blood, 2011 Dec 14; 119(12). PMID: 22160384    Free PMC article.
Highly Cited.
Chimeric antibody receptors (CARs): driving T-cell specificity to enhance anti-tumor immunity.
Partow Kebriaei, Susan S Kelly, +5 authors, Laurence J N Cooper.
Front Biosci (Schol Ed), 2011 Dec 29; 4(2). PMID: 22202074    Free PMC article.
Immunology in the clinic review series; focus on cancer: double trouble for tumours: bi-functional and redirected T cells as effective cancer immunotherapies.
L A Marr, D E Gilham, J D M Campbell, A R Fraser.
Clin Exp Immunol, 2012 Jan 13; 167(2). PMID: 22235997    Free PMC article.
Armed and accurate: engineering cytotoxic T cells for eradication of leukemia.
Marko Radic.
BMC Biotechnol, 2012 Feb 10; 12. PMID: 22316161    Free PMC article.
Redirecting T cells to Ewing's sarcoma family of tumors by a chimeric NKG2D receptor expressed by lentiviral transduction or mRNA transfection.
Manfred Lehner, Gabriel Götz, +11 authors, Wolfgang Holter.
PLoS One, 2012 Feb 23; 7(2). PMID: 22355347    Free PMC article.
Anti-TCRβ mAb induces long-term allograft survival by reducing antigen-reactive T cells and sparing regulatory T cells.
Y Miyahara, M Khattar, +6 authors, S M Stepkowski.
Am J Transplant, 2012 Mar 17; 12(6). PMID: 22420295    Free PMC article.
Adoptive immunotherapy for cancer: harnessing the T cell response.
Nicholas P Restifo, Mark E Dudley, Steven A Rosenberg.
Nat Rev Immunol, 2012 Mar 23; 12(4). PMID: 22437939    Free PMC article.
Highly Cited. Review.
A new cellular weapon to kill leukaemic B-cells.
Mohamed-Rachid Boulassel.
Sultan Qaboos Univ Med J, 2012 May 02; 12(2). PMID: 22548131    Free PMC article.
Chimeric antigen receptor T cells shape myeloid cell function within the tumor microenvironment through IFN-γ and GM-CSF.
Paul Spear, Amorette Barber, Agnieszka Rynda-Apple, Charles L Sentman.
J Immunol, 2012 May 16; 188(12). PMID: 22586039    Free PMC article.
Passive immunotherapeutic strategies for the treatment of malignant gliomas.
Daniel T Nagasawa, Christina Fong, +4 authors, Isaac Yang.
Neurosurg Clin N Am, 2012 Jul 04; 23(3). PMID: 22748660    Free PMC article.
An NKp30-based chimeric antigen receptor promotes T cell effector functions and antitumor efficacy in vivo.
Tong Zhang, Ming-Ru Wu, Charles L Sentman.
J Immunol, 2012 Aug 02; 189(5). PMID: 22851709    Free PMC article.
Suppression of human glioma xenografts with second-generation IL13R-specific chimeric antigen receptor-modified T cells.
Seogkyoung Kong, Sadhak Sengupta, +9 authors, Prakash Sampath.
Clin Cancer Res, 2012 Sep 12; 18(21). PMID: 22966020    Free PMC article.
Advances in the development of cancer immunotherapies.
Jianjun Gao, Chantale Bernatchez, +2 authors, Patrick Hwu.
Trends Immunol, 2012 Oct 04; 34(2). PMID: 23031830    Free PMC article.
Phenotypic and functional attributes of lentivirus-modified CD19-specific human CD8+ central memory T cells manufactured at clinical scale.
Xiuli Wang, Araceli Naranjo, +8 authors, Michael C Jensen.
J Immunother, 2012 Oct 24; 35(9). PMID: 23090078    Free PMC article.
The past, present, and future of adoptive T cell therapy.
Donghoon Choi, Tai-Gyu Kim, Young Chul Sung.
Immune Netw, 2012 Oct 24; 12(4). PMID: 23091437    Free PMC article.
CARs in chronic lymphocytic leukemia -- ready to drive.
Chitra Hosing, Partow Kebriaei, +3 authors, Elizabeth Shpall.
Curr Hematol Malig Rep, 2012 Dec 12; 8(1). PMID: 23225251    Free PMC article.
Novel cellular therapies for leukemia: CAR-modified T cells targeted to the CD19 antigen.
Renier J Brentjens, Kevin J Curran.
Hematology Am Soc Hematol Educ Program, 2012 Dec 13; 2012. PMID: 23233573    Free PMC article.
Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells.
Christopher C Kloss, Maud Condomines, +2 authors, Michel Sadelain.
Nat Biotechnol, 2012 Dec 18; 31(1). PMID: 23242161    Free PMC article.
Highly Cited.
How do CARs work?: Early insights from recent clinical studies targeting CD19.
Marco L Davila, Renier Brentjens, +2 authors, Michel Sadelain.
Oncoimmunology, 2012 Dec 25; 1(9). PMID: 23264903    Free PMC article.
Immunotherapy for B-Cell Neoplasms using T Cells expressing Chimeric Antigen Receptors: From antigen choice to clinical implementation.
Mohamed-Rachid Boulassel, Ahmed Galal.
Sultan Qaboos Univ Med J, 2012 Dec 28; 12(3). PMID: 23269948    Free PMC article.
Developing strategies in the immunotherapy of leukemias.
Jason B Brayer, Javier Pinilla-Ibarz.
Cancer Control, 2013 Jan 11; 20(1). PMID: 23302907    Free PMC article.
Clinical-scale derivation of natural killer cells from human pluripotent stem cells for cancer therapy.
David A Knorr, Zhenya Ni, +5 authors, Dan S Kaufman.
Stem Cells Transl Med, 2013 Mar 22; 2(4). PMID: 23515118    Free PMC article.
Highly Cited.
CD20-targeted T cells after stem cell transplantation for high risk and refractory non-Hodgkin's lymphoma.
Lawrence G Lum, Archana Thakur, +13 authors, Voravit Ratanatharathorn.
Biol Blood Marrow Transplant, 2013 Mar 27; 19(6). PMID: 23529012    Free PMC article.
Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors.
James N Kochenderfer, Steven A Rosenberg.
Nat Rev Clin Oncol, 2013 Apr 03; 10(5). PMID: 23546520    Free PMC article.
Highly Cited. Review.
The basic principles of chimeric antigen receptor design.
Michel Sadelain, Renier Brentjens, Isabelle Rivière.
Cancer Discov, 2013 Apr 04; 3(4). PMID: 23550147    Free PMC article.
Highly Cited. Review.
Systems model of T cell receptor proximal signaling reveals emergent ultrasensitivity.
Himadri Mukhopadhyay, Shaun-Paul Cordoba, +2 authors, Omer Dushek.
PLoS Comput Biol, 2013 Apr 05; 9(3). PMID: 23555234    Free PMC article.
NKG2D CAR T-cell therapy inhibits the growth of NKG2D ligand heterogeneous tumors.
Paul Spear, Amorette Barber, Agnieszka Rynda-Apple, Charles L Sentman.
Immunol Cell Biol, 2013 May 01; 91(6). PMID: 23628805    Free PMC article.
Immune targeting of fibroblast activation protein triggers recognition of multipotent bone marrow stromal cells and cachexia.
Eric Tran, Dhanalakshmi Chinnasamy, +4 authors, Steven A Rosenberg.
J Exp Med, 2013 May 29; 210(6). PMID: 23712432    Free PMC article.
Highly Cited.
Collaboration of chimeric antigen receptor (CAR)-expressing T cells and host T cells for optimal elimination of established ovarian tumors.
Paul Spear, Amorette Barber, Charles L Sentman.
Oncoimmunology, 2013 Jun 05; 2(4). PMID: 23734311    Free PMC article.
Altering cell death pathways as an approach to cure HIV infection.
A D Badley, A Sainski, F Wightman, S R Lewin.
Cell Death Dis, 2013 Jul 13; 4. PMID: 23846220    Free PMC article.
Mesothelin-targeted immunotherapies for malignant pleural mesothelioma.
Jonathan Villena-Vargas, Prasad S Adusumilli.
Ann Cardiothorac Surg, 2013 Aug 27; 1(4). PMID: 23977538    Free PMC article.
Interleukin-7 mediates selective expansion of tumor-redirected cytotoxic T lymphocytes (CTLs) without enhancement of regulatory T-cell inhibition.
Serena K Perna, Daria Pagliara, +4 authors, Gianpietro Dotti.
Clin Cancer Res, 2013 Oct 08; 20(1). PMID: 24097874    Free PMC article.
New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.
Lindsay Am Rein, Anthony D Sung, David A Rizzieri.
Int J Hematol Oncol, 2013 Dec 05; 2(1). PMID: 24303095    Free PMC article.
A new approach to gene therapy using Sleeping Beauty to genetically modify clinical-grade T cells to target CD19.
Harjeet Singh, Helen Huls, Partow Kebriaei, Laurence J N Cooper.
Immunol Rev, 2013 Dec 18; 257(1). PMID: 24329797    Free PMC article.
T lymphocytes redirected against the chondroitin sulfate proteoglycan-4 control the growth of multiple solid tumors both in vitro and in vivo.
Claudia Geldres, Barbara Savoldo, +8 authors, Gianpietro Dotti.
Clin Cancer Res, 2013 Dec 18; 20(4). PMID: 24334762    Free PMC article.
PD-1- and CTLA-4-based inhibitory chimeric antigen receptors (iCARs) divert off-target immunotherapy responses.
Victor D Fedorov, Maria Themeli, Michel Sadelain.
Sci Transl Med, 2013 Dec 18; 5(215). PMID: 24337479    Free PMC article.
Highly Cited.
Hunting for clinical translation with innate-like immune cells and their receptors.
W Scheper, C Gründer, +2 authors, J Kuball.
Leukemia, 2013 Dec 19; 28(6). PMID: 24345790
Chimeric antigen receptor T Cells with dissociated signaling domains exhibit focused antitumor activity with reduced potential for toxicity in vivo.
Evripidis Lanitis, Mathilde Poussin, +4 authors, Daniel J Powell.
Cancer Immunol Res, 2014 Jan 11; 1(1). PMID: 24409448    Free PMC article.
Highly Cited.
Chronic lymphocytic leukemia: inception to cure: are we there?
Deepesh P Lad, Pankaj Malhotra, Subhash Varma.
Indian J Hematol Blood Transfus, 2014 Jan 16; 29(1). PMID: 24426325    Free PMC article.
Systemic treatment with CAR-engineered T cells against PSCA delays subcutaneous tumor growth and prolongs survival of mice.
Victoria Hillerdal, Mohanraj Ramachandran, Justyna Leja, Magnus Essand.
BMC Cancer, 2014 Jan 21; 14. PMID: 24438073    Free PMC article.
Rise of iPSCs as a cell source for adoptive immunotherapy.
Atsutaka Minagawa, Shin Kaneko.
Hum Cell, 2014 Feb 11; 27(2). PMID: 24510519
Primer on tumor immunology and cancer immunotherapy.
Timothy J Harris, Charles G Drake.
J Immunother Cancer, 2013 Jan 01; 1. PMID: 24829749    Free PMC article.
Clinical application of adoptive T cell therapy in solid tumors.
Yi-Wen Zang, Xiao-Dong Gu, Jian-Bin Xiang, Zong-You Chen.
Med Sci Monit, 2014 Jun 11; 20. PMID: 24912947    Free PMC article.
Synthetic biology for therapeutic applications.
Zhanar Abil, Xiong Xiong, Huimin Zhao.
Mol Pharm, 2014 Aug 08; 12(2). PMID: 25098838    Free PMC article.
Phenotypic models of T cell activation.
Melissa Lever, Philip K Maini, P Anton van der Merwe, Omer Dushek.
Nat Rev Immunol, 2014 Aug 26; 14(9). PMID: 25145757
T-cell immunotherapy: looking forward.
Jacqueline Corrigan-Curay, Hans-Peter Kiem, +23 authors, Donald B Kohn.
Mol Ther, 2014 Sep 05; 22(9). PMID: 25186558    Free PMC article.
Targeting CD8+ T-cell tolerance for cancer immunotherapy.
Stephanie R Jackson, Jinyun Yuan, Ryan M Teague.
Immunotherapy, 2014 Oct 08; 6(7). PMID: 25290416    Free PMC article.
Enhanced cytotoxicity of natural killer cells following the acquisition of chimeric antigen receptors through trogocytosis.
Fu-Nan Cho, Tsung-Hsien Chang, +9 authors, Yu-Hsiang Chang.
PLoS One, 2014 Oct 15; 9(10). PMID: 25313995    Free PMC article.
Are natural killer cells superior CAR drivers?
Hans Klingemann.
Oncoimmunology, 2014 Oct 24; 3. PMID: 25340009    Free PMC article.
Highly Cited.
One-step enzymatic modification of the cell surface redirects cellular cytotoxicity and parasite tropism.
Lee Kim Swee, Sebastian Lourido, +2 authors, Hidde L Ploegh.
ACS Chem Biol, 2014 Nov 02; 10(2). PMID: 25360987    Free PMC article.
Matrix-specific anchors: a new concept for targeted delivery and retention of therapeutic cells.
Andrzej Steplewski, Jolanta Fertala, +2 authors, Andrzej Fertala.
Tissue Eng Part A, 2014 Dec 02; 21(7-8). PMID: 25435302    Free PMC article.
Novel immunotherapies for hematologic malignancies.
Michelle H Nelson, Chrystal M Paulos.
Immunol Rev, 2014 Dec 17; 263(1). PMID: 25510273    Free PMC article.
Manufacture of T cells using the Sleeping Beauty system to enforce expression of a CD19-specific chimeric antigen receptor.
H Singh, J S E Moyes, M H Huls, L J N Cooper.
Cancer Gene Ther, 2015 Jan 17; 22(2). PMID: 25591810
New cell sources for T cell engineering and adoptive immunotherapy.
Maria Themeli, Isabelle Rivière, Michel Sadelain.
Cell Stem Cell, 2015 Apr 07; 16(4). PMID: 25842976    Free PMC article.
Phase I Hepatic Immunotherapy for Metastases Study of Intra-Arterial Chimeric Antigen Receptor-Modified T-cell Therapy for CEA+ Liver Metastases.
Steven C Katz, Rachel A Burga, +11 authors, Richard P Junghans.
Clin Cancer Res, 2015 Apr 09; 21(14). PMID: 25850950    Free PMC article.
Highly Cited.
Immunotherapy for hepatocellular carcinoma: From basic research to clinical use.
Yu-Peng Hong, Zi-Duo Li, Pankaj Prasoon, Qi Zhang.
World J Hepatol, 2015 May 09; 7(7). PMID: 25954480    Free PMC article.
Identification and selective expansion of functionally superior T cells expressing chimeric antigen receptors.
ZeNan L Chang, Pamela A Silver, Yvonne Y Chen.
J Transl Med, 2015 May 21; 13. PMID: 25990251    Free PMC article.
Challenges and future perspectives of T cell immunotherapy in cancer.
Maria Teresa P de Aquino, Anshu Malhotra, Manoj K Mishra, Anil Shanker.
Immunol Lett, 2015 Jun 23; 166(2). PMID: 26096822    Free PMC article.
The pharmacology of second-generation chimeric antigen receptors.
Sjoukje J C van der Stegen, Mohamad Hamieh, Michel Sadelain.
Nat Rev Drug Discov, 2015 Jul 02; 14(7). PMID: 26129802    Free PMC article.
Highly Cited. Review.
Genetic instability in the tumor microenvironment: a new look at an old neighbor.
Antonio Palumbo, Nathalia de Oliveira Meireles Da Costa, +2 authors, Luiz Eurico Nasciutti.
Mol Cancer, 2015 Aug 01; 14. PMID: 26227631    Free PMC article.
A novel anti-GD2/4-1BB chimeric antigen receptor triggers neuroblastoma cell killing.
Malvina Prapa, Sara Caldrer, +9 authors, Massimo Dominici.
Oncotarget, 2015 Aug 25; 6(28). PMID: 26298772    Free PMC article.
CAR therapy: the CD19 paradigm.
Michel Sadelain.
J Clin Invest, 2015 Sep 02; 125(9). PMID: 26325036    Free PMC article.
Highly Cited. Review.
Adoptive immunotherapy for acute leukemia: New insights in chimeric antigen receptors.
Maël Heiblig, Mohamed Elhamri, Mauricette Michallet, Xavier Thomas.
World J Stem Cells, 2015 Sep 04; 7(7). PMID: 26328018    Free PMC article.
Rigorous optimization and validation of potent RNA CAR T cell therapy for the treatment of common epithelial cancers expressing folate receptor.
Keith Schutsky, D Gang Song, +5 authors, Daniel J Powell.
Oncotarget, 2015 Sep 12; 6(30). PMID: 26359629    Free PMC article.
Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells.
Zeguo Zhao, Maud Condomines, +5 authors, Michel Sadelain.
Cancer Cell, 2015 Oct 16; 28(4). PMID: 26461090    Free PMC article.
Highly Cited.
Novel drug targets for personalized precision medicine in relapsed/refractory diffuse large B-cell lymphoma: a comprehensive review.
Rosalba Camicia, Hans C Winkler, Paul O Hassa.
Mol Cancer, 2015 Dec 15; 14. PMID: 26654227    Free PMC article.
Computational selection of antibody-drug conjugate targets for breast cancer.
François Fauteux, Jennifer J Hill, +4 authors, Maureen O'Connor-McCourt.
Oncotarget, 2015 Dec 25; 7(3). PMID: 26700623    Free PMC article.
Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits.
Kole T Roybal, Levi J Rupp, +4 authors, Wendell A Lim.
Cell, 2016 Feb 03; 164(4). PMID: 26830879    Free PMC article.
Highly Cited.
Chimeric Antigen Receptor-Modified T Cells for Solid Tumors: Challenges and Prospects.
Yelei Guo, Yao Wang, Weidong Han.
J Immunol Res, 2016 Mar 22; 2016. PMID: 26998495    Free PMC article.
Alloantigen-specific regulatory T cells generated with a chimeric antigen receptor.
Katherine G MacDonald, Romy E Hoeppli, +5 authors, Megan K Levings.
J Clin Invest, 2016 Mar 22; 126(4). PMID: 26999600    Free PMC article.
Highly Cited.
Cancer Immunotherapy for Gliomas: Overview and Future Directions.
Naoya Hashimoto.
Neurol Med Chir (Tokyo), 2016 Apr 19; 56(7). PMID: 27087194    Free PMC article.
Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies.
K Roellecke, E L Virts, +11 authors, H Hanenberg.
Gene Ther, 2016 Apr 20; 23(7). PMID: 27092941
Regression of established renal cell carcinoma in nude mice using lentivirus-transduced human T cells expressing a human anti-CAIX chimeric antigen receptor.
Agnes Shuk-Yee Lo, Chen Xu, Akikazu Murakami, Wayne A Marasco.
Mol Ther Oncolytics, 2014 Jan 01; 1. PMID: 27119093    Free PMC article.
Chimeric antigen receptor-engineered T cells as oncolytic virus carriers.
Heather VanSeggelen, Daniela Gm Tantalo, +2 authors, Jonathan L Bramson.
Mol Ther Oncolytics, 2015 Jan 01; 2. PMID: 27119109    Free PMC article.
Strategies to genetically engineer T cells for cancer immunotherapy.
Timothy T Spear, Kaoru Nagato, Michael I Nishimura.
Cancer Immunol Immunother, 2016 May 04; 65(6). PMID: 27138532    Free PMC article.
Opportunities in immunotherapy of ovarian cancer.
G Coukos, J Tanyi, L E Kandalaft.
Ann Oncol, 2016 May 04; 27 Suppl 1. PMID: 27141063    Free PMC article.
Biology and clinical application of CAR T cells for B cell malignancies.
Marco L Davila, Michel Sadelain.
Int J Hematol, 2016 Jun 06; 104(1). PMID: 27262700    Free PMC article.
A Functionally Superior Second-Generation Vector Expressing an Aurora Kinase-A-Specific T-Cell Receptor for Anti-Leukaemia Adoptive Immunotherapy.
Nicholas Paul Casey, Hiroshi Fujiwara, +5 authors, Masaki Yasukawa.
PLoS One, 2016 Jun 09; 11(6). PMID: 27271876    Free PMC article.
Chimeric antigen receptors: driving immunology towards synthetic biology.
Michel Sadelain.
Curr Opin Immunol, 2016 Jul 04; 41. PMID: 27372731    Free PMC article.
Binding of the cytoplasmic domain of CD28 to the plasma membrane inhibits Lck recruitment and signaling.
Jessica Dobbins, Etienne Gagnon, +4 authors, Kai W Wucherpfennig.
Sci Signal, 2016 Jul 28; 9(438). PMID: 27460989    Free PMC article.
Producer T cells: Using genetically engineered T cells as vehicles to generate and deliver therapeutics to tumors.
Alexander K Tsai, Eduardo Davila.
Oncoimmunology, 2016 Jul 29; 5(5). PMID: 27467930    Free PMC article.
Architecture of a minimal signaling pathway explains the T-cell response to a 1 million-fold variation in antigen affinity and dose.
Melissa Lever, Hong-Sheng Lim, +6 authors, Omer Dushek.
Proc Natl Acad Sci U S A, 2016 Oct 30; 113(43). PMID: 27702900    Free PMC article.
Immunoproteasome deficiency in non-small cell lung cancer and its relevance to immunotherapy.
Juergen Kast.
J Thorac Dis, 2016 Oct 18; 8(9). PMID: 27747070    Free PMC article.
Combining Cell and Gene Therapy in an Effort to Eradicate HIV.
Thor A Wagner.
AIDS Patient Care STDS, 2016 Dec 03; 30(12). PMID: 27905840    Free PMC article.
Immunological quality and performance of tumor vessel-targeting CAR-T cells prepared by mRNA-EP for clinical research.
Kanako Inoo, Ryo Inagaki, +4 authors, Naoki Okada.
Mol Ther Oncolytics, 2016 Dec 03; 3. PMID: 27909701    Free PMC article.
Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia.
Noelle V Frey, David L Porter.
Hematology Am Soc Hematol Educ Program, 2016 Dec 04; 2016(1). PMID: 27913530    Free PMC article.
Regulatory T cells: tolerance induction in solid organ transplantation.
T Vaikunthanathan, N Safinia, +2 authors, G Lombardi.
Clin Exp Immunol, 2017 Apr 20; 189(2). PMID: 28422316    Free PMC article.
Chimeric Antigen Receptors: A Cell and Gene Therapy Perspective.
Isabelle Rivière, Michel Sadelain.
Mol Ther, 2017 May 01; 25(5). PMID: 28456379    Free PMC article.
Engineering Chimeric Antigen Receptors.
S V Kulemzin, V V Kuznetsova, +2 authors, A A Gorchakov.
Acta Naturae, 2017 May 04; 9(1). PMID: 28461969    Free PMC article.
FCγ Chimeric Receptor-Engineered T Cells: Methodology, Advantages, Limitations, and Clinical Relevance.
Sara Caratelli, Tommaso Sconocchia, +9 authors, Giuseppe Sconocchia.
Front Immunol, 2017 May 13; 8. PMID: 28496440    Free PMC article.
Therapeutic T cell engineering.
Michel Sadelain, Isabelle Rivière, Stanley Riddell.
Nature, 2017 May 26; 545(7655). PMID: 28541315    Free PMC article.
Highly Cited. Review.
Chimeric antigen receptor modified T cells that target chemokine receptor CCR4 as a therapeutic modality for T-cell malignancies.
Liyanage P Perera, Meili Zhang, +5 authors, Pin-Yu Perera.
Am J Hematol, 2017 May 26; 92(9). PMID: 28543380    Free PMC article.
Inducible Activation of MyD88 and CD40 in CAR T Cells Results in Controllable and Potent Antitumor Activity in Preclinical Solid Tumor Models.
Melinda Mata, Claudia Gerken, +3 authors, Stephen Gottschalk.
Cancer Discov, 2017 Aug 13; 7(11). PMID: 28801306    Free PMC article.
Chimeric antigen receptor T-cell therapies for lymphoma.
Jennifer N Brudno, James N Kochenderfer.
Nat Rev Clin Oncol, 2017 Sep 01; 15(1). PMID: 28857075
Highly Cited. Review.
CAR-T cell therapy in ovarian cancer: from the bench to the bedside.
Xinxin Zhu, Han Cai, +2 authors, Jinghe Lang.
Oncotarget, 2017 Oct 04; 8(38). PMID: 28969098    Free PMC article.
Characterization of a switchable chimeric antigen receptor platform in a pre-clinical solid tumor model.
Elham Pishali Bejestani, Marc Cartellieri, +14 authors, Malte von Bonin.
Oncoimmunology, 2017 Nov 11; 6(10). PMID: 29123951    Free PMC article.
Prospects for chimeric antigen receptor-modified T cell therapy for solid tumors.
Erhao Zhang, Jieyi Gu, Hanmei Xu.
Mol Cancer, 2018 Jan 14; 17(1). PMID: 29329591    Free PMC article.
Current state and future prospects of immunotherapy for glioma.
Neha Kamran, Mahmoud S Alghamri, +6 authors, Maria G Castro.
Immunotherapy, 2018 Feb 10; 10(4). PMID: 29421984    Free PMC article.
Quarter Century of Anti-HIV CAR T Cells.
Thor A Wagner.
Curr HIV/AIDS Rep, 2018 Mar 04; 15(2). PMID: 29500712    Free PMC article.
Immunological Synapse Predicts Effectiveness of Chimeric Antigen Receptor Cells.
Wei Xiong, Yuhui Chen, +8 authors, Dongfang Liu.
Mol Ther, 2018 Mar 06; 26(4). PMID: 29503199    Free PMC article.
CD19 CAR-T cell therapy for relapsed/refractory acute lymphoblastic leukemia: factors affecting toxicities and long-term efficacies.
Li-Na Zhang, Yongping Song, Delong Liu.
J Hematol Oncol, 2018 Mar 17; 11(1). PMID: 29544528    Free PMC article.
The development of CAR design for tumor CAR-T cell therapy.
Dandan Xu, Guoliang Jin, +5 authors, Junnian Zheng.
Oncotarget, 2018 Mar 24; 9(17). PMID: 29568411    Free PMC article.
Versatile CAR T-cells for cancer immunotherapy.
Fuliang Chu, Jingjing Cao, Sattva S Neelalpu.
Contemp Oncol (Pozn), 2018 Apr 10; 22(1A). PMID: 29628798    Free PMC article.
PET of Adoptively Transferred Chimeric Antigen Receptor T Cells with 89Zr-Oxine.
Michael R Weist, Renate Starr, +10 authors, John E Shively.
J Nucl Med, 2018 May 08; 59(10). PMID: 29728514    Free PMC article.
Are ovarian cancer stem cells the target for innovative immunotherapy?
Liang Wang, Tianmin Xu, Manhua Cui.
Onco Targets Ther, 2018 May 22; 11. PMID: 29780254    Free PMC article.
Choice of costimulatory domains and of cytokines determines CAR T-cell activity in neuroblastoma.
Concetta Quintarelli, Domenico Orlando, +14 authors, Ignazio Caruana.
Oncoimmunology, 2018 Jun 07; 7(6). PMID: 29872565    Free PMC article.
Ovarian Cancer Immunotherapy: Preclinical Models and Emerging Therapeutics.
Curtis W McCloskey, Galaxia M Rodriguez, Kristianne J C Galpin, Barbara C Vanderhyden.
Cancers (Basel), 2018 Jul 28; 10(8). PMID: 30049987    Free PMC article.
Studying cancer immunotherapy using patient-derived xenografts (PDXs) in humanized mice.
Yunsik Choi, Sanghyuk Lee, +3 authors, Charles Lee.
Exp Mol Med, 2018 Aug 10; 50(8). PMID: 30089794    Free PMC article.
Immunotherapy in Prostate Cancer: Teaching an Old Dog New Tricks.
Michael C Comiskey, Matthew C Dallos, Charles G Drake.
Curr Oncol Rep, 2018 Aug 19; 20(9). PMID: 30120592
Conventional CARs versus modular CARs.
Anja Feldmann, Claudia Arndt, +3 authors, Michael P Bachmann.
Cancer Immunol Immunother, 2019 Sep 23; 68(10). PMID: 31542798    Free PMC article.
En masse discovery of anti-cancer human monoclonal antibodies by de novo assembly of immunoglobulin sequences from transcriptomes and genome sequences of cancer tissues.
Peng Zhang, Hung-Yen Chou, +2 authors, Yang Liu.
Cell Mol Immunol, 2019 Sep 29; 16(12). PMID: 31562388    Free PMC article.
CARdiac Immunotherapy: T Cells Engineered to Treat the Fibrotic Heart.
Ronald J Vagnozzi, Anne Katrine Z Johansen, Jeffery D Molkentin.
Mol Ther, 2019 Oct 06; 27(11). PMID: 31585799    Free PMC article.
Advances Of Chimeric Antigen Receptor T Cell Therapy In Ovarian Cancer.
Wenying Yan, Hongmei Hu, Biao Tang.
Onco Targets Ther, 2019 Nov 07; 12. PMID: 31686857    Free PMC article.
Ovarian cancer: Current status and strategies for improving therapeutic outcomes.
Ashwin Chandra, Cima Pius, +4 authors, Riyaz Basha.
Cancer Med, 2019 Sep 29; 8(16). PMID: 31560828    Free PMC article.
Understanding the Mechanisms of Resistance to CAR T-Cell Therapy in Malignancies.
Jiali Cheng, Lei Zhao, +5 authors, Jianfeng Zhou.
Front Oncol, 2019 Dec 12; 9. PMID: 31824840    Free PMC article.
Potential of Glioblastoma-Targeted Chimeric Antigen Receptor (CAR) T-Cell Therapy.
Ryan D Salinas, Joseph S Durgin, Donald M O'Rourke.
CNS Drugs, 2020 Jan 10; 34(2). PMID: 31916100
The long road to the first FDA-approved gene therapy: chimeric antigen receptor T cells targeting CD19.
Peter Braendstrup, Bruce L Levine, Marco Ruella.
Cytotherapy, 2020 Feb 06; 22(2). PMID: 32014447    Free PMC article.
T cell receptor-based cancer immunotherapy: Emerging efficacy and pathways of resistance.
Smita S Chandran, Christopher A Klebanoff.
Immunol Rev, 2019 Jul 30; 290(1). PMID: 31355495    Free PMC article.
Highly Cited. Review.
An oligo-His-tag of a targeting module does not influence its biodistribution and the retargeting capabilities of UniCAR T cells.
Justyna Jureczek, Ralf Bergmann, +7 authors, Anja Feldmann.
Sci Rep, 2019 Jul 25; 9(1). PMID: 31332252    Free PMC article.
Off-the-shelf cell therapy with induced pluripotent stem cell-derived natural killer cells.
Michelle L Saetersmoen, Quirin Hammer, +2 authors, Karl-Johan Malmberg.
Semin Immunopathol, 2018 Oct 27; 41(1). PMID: 30361801
Advances in Developing CAR T-Cell Therapy for HIV Cure.
Jinxin Qi, Chengchao Ding, Xian Jiang, Yong Gao.
Front Immunol, 2020 Mar 27; 11. PMID: 32210965    Free PMC article.
Cell Adhesion Molecules and Their Roles and Regulation in the Immune and Tumor Microenvironment.
Heidi Harjunpää, Marc Llort Asens, Carla Guenther, Susanna C Fagerholm.
Front Immunol, 2019 Jun 25; 10. PMID: 31231358    Free PMC article.
Highly Cited. Review.
Is TCR/pMHC Affinity a Good Estimate of the T-cell Response? An Answer Based on Predictions From 12 Phenotypic Models.
Jesús Gálvez, Juan J Gálvez, Pilar García-Peñarrubia.
Front Immunol, 2019 Mar 20; 10. PMID: 30886616    Free PMC article.
Applications and explorations of CRISPR/Cas9 in CAR T-cell therapy.
Chenggong Li, Heng Mei, Yu Hu.
Brief Funct Genomics, 2020 Jan 18; 19(3). PMID: 31950135    Free PMC article.
Chimeric antigen receptor signaling: Functional consequences and design implications.
S E Lindner, S M Johnson, C E Brown, L D Wang.
Sci Adv, 2020 Jul 09; 6(21). PMID: 32637585    Free PMC article.
[Construction of CD19-CAR retroviral vector and modification of its transduction of human T-lymphocytes].
Yang Wang, Gusheng Tang, +9 authors, Jianmin Yang.
Zhonghua Xue Ye Xue Za Zhi, 2015 Apr 29; 36(4). PMID: 25916298    Free PMC article.
[Cytotoxity of pomalidomide combined CAR-T cell for multiple myeloma cell RPMI8226 and U266].
Lei Wang, Shuting Zhang, Jianfeng Ou, Hai Bai.
Zhonghua Xue Ye Xue Za Zhi, 2015 Jul 03; 36(6). PMID: 26134016    Free PMC article.
Applications of genome editing technology in the targeted therapy of human diseases: mechanisms, advances and prospects.
Hongyi Li, Yang Yang, +3 authors, Xia Zhao.
Signal Transduct Target Ther, 2020 Apr 17; 5(1). PMID: 32296011    Free PMC article.
CAR-T design: Elements and their synergistic function.
Jayapriya Jayaraman, Michael P Mellody, +5 authors, Weian Zhao.
EBioMedicine, 2020 Aug 03; 58. PMID: 32739874    Free PMC article.
Chimeric Antigen Receptor Therapy.
Carl H June, Michel Sadelain.
N Engl J Med, 2018 Jul 05; 379(1). PMID: 29972754    Free PMC article.
Highly Cited. Review.
Current Clinical Evidence and Potential Solutions to Increase Benefit of CAR T-Cell Therapy for Patients with Solid Tumors.
Marion Alcantara, Pauline Du Rusquec, Emanuela Romano.
Oncoimmunology, 2020 Sep 17; 9(1). PMID: 32934880    Free PMC article.
Chimeric Antigen Receptor T-Cell Therapy: A Beacon of Hope in the Fight Against Cancer.
Syed Maaz Tariq, Syed Ali Haider, +4 authors, Anum Kamal.
Cureus, 2019 Jan 08; 10(10). PMID: 30613448    Free PMC article.
Functional Analysis of an Inducible Promoter Driven by Activation Signals from a Chimeric Antigen Receptor.
Ryosuke Uchibori, Takeshi Teruya, +6 authors, Keiya Ozawa.
Mol Ther Oncolytics, 2019 Jan 22; 12. PMID: 30662937    Free PMC article.
Antibodies and Derivatives Targeting DR4 and DR5 for Cancer Therapy.
Agathe Dubuisson, Olivier Micheau.
Antibodies (Basel), 2017 Oct 25; 6(4). PMID: 31548531    Free PMC article.
Robust expansion of HIV CAR T cells following antigen boosting in ART-suppressed nonhuman primates.
Blake J Rust, Leslie S Kean, +13 authors, Christopher W Peterson.
Blood, 2020 Jul 03; 136(15). PMID: 32614969    Free PMC article.
Hepatocellular Carcinoma-The Influence of Immunoanatomy and the Role of Immunotherapy.
Keyur Patel, Ryan Lamm, +2 authors, Ashesh P Shah.
Int J Mol Sci, 2020 Sep 19; 21(18). PMID: 32942580    Free PMC article.
Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit?
Hui Yi Chew, Victor Chan, Fiona Simpson, Riccardo Dolcetti.
Cancers (Basel), 2020 Nov 20; 12(11). PMID: 33207697    Free PMC article.
Adoptive cell therapy: genetic modification to redirect effector cell specificity.
Richard A Morgan, Mark E Dudley, Steven A Rosenberg.
Cancer J, 2010 Aug 10; 16(4). PMID: 20693844    Free PMC article.
Current Immunotherapy Approaches in Non-Hodgkin Lymphomas.
Robert Pytlik, Kamila Polgarova, Jana Karolova, Pavel Klener.
Vaccines (Basel), 2020 Dec 03; 8(4). PMID: 33260966    Free PMC article.
Noninvasive Imaging of Cancer Immunotherapy.
Omar Abousaway, Taha Rakhshandehroo, +2 authors, Mohammad Rashidian.
Nanotheranostics, 2021 Jan 05; 5(1). PMID: 33391977    Free PMC article.
Current and future immunotherapy approaches in ovarian cancer.
Nazım Can Demircan, Stergios Boussios, Tolga Tasci, Mehmet Akif Öztürk.
Ann Transl Med, 2021 Jan 26; 8(24). PMID: 33490226    Free PMC article.
Proceedings From the First International Workshop at Sidra Medicine: "Engineered Immune Cells in Cancer Immunotherapy (EICCI): From Discovery to Off-the-Shelf Development", 15th-16th February 2019, Doha, Qatar.
Bella Guerrouahen, Muhammad Elnaggar, +15 authors, EICCI Faculty Group.
Front Immunol, 2021 Feb 16; 11. PMID: 33584653    Free PMC article.
CAR T Cell Therapy in Pancreaticobiliary Cancers: a Focused Review of Clinical Data.
Muhammad Yasir Anwar, Grant R Williams, Ravi K Paluri.
J Gastrointest Cancer, 2020 Jul 24; 52(1). PMID: 32700185
BAY 60-6583 Enhances the Antitumor Function of Chimeric Antigen Receptor-Modified T Cells Independent of the Adenosine A2b Receptor.
Jiaxing Tang, Yan Zou, +6 authors, Xuekai Zhu.
Front Pharmacol, 2021 Mar 30; 12. PMID: 33776765    Free PMC article.
Novel approaches to enhance the specificity and safety of engineered T cells.
Victor D Fedorov, Michel Sadelain, Christopher C Kloss.
Cancer J, 2014 Mar 29; 20(2). PMID: 24667964    Free PMC article.
Immunosuppressive Effects of Myeloid-Derived Suppressor Cells in Cancer and Immunotherapy.
Mithunah Krishnamoorthy, Lara Gerhardt, Saman Maleki Vareki.
Cells, 2021 Jun 03; 10(5). PMID: 34065010    Free PMC article.
Theranostic cells: emerging clinical applications of synthetic biology.
Monica P McNerney, Kailyn E Doiron, +2 authors, Pamela A Silver.
Nat Rev Genet, 2021 Jul 09; 22(11). PMID: 34234299    Free PMC article.
Chimeric Antigen Receptor-T Cells: A Pharmaceutical Scope.
Alejandrina Hernández-López, Mario A Téllez-González, Paul Mondragón-Terán, Angélica Meneses-Acosta.
Front Pharmacol, 2021 Sep 08; 12. PMID: 34489708    Free PMC article.
Chimeric Antigen Receptor T-Cell Therapy: The Light of Day for Osteosarcoma.
Zili Lin, Ziyi Wu, Wei Luo.
Cancers (Basel), 2021 Sep 11; 13(17). PMID: 34503279    Free PMC article.
Chimeric antigen receptor (CAR) immunotherapy: basic principles, current advances, and future prospects in neuro-oncology.
Hyeon Joo Yoo, Biyan Nathanael Harapan.
Immunol Res, 2021 Sep 24; 69(6). PMID: 34554405    Free PMC article.
A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy.
Zili Lin, Ziyi Wu, Wei Luo.
Front Immunol, 2021 Sep 28; 12. PMID: 34566963    Free PMC article.
Advances in Universal CAR-T Cell Therapy.
Haolong Lin, Jiali Cheng, +2 authors, Li Zhu.
Front Immunol, 2021 Oct 26; 12. PMID: 34691052    Free PMC article.
Effective chimeric antigen receptor T cells against SARS-CoV-2.
Xueyang Guo, Alexandra Kazanova, +2 authors, Christopher E Rudd.
iScience, 2021 Oct 26; 24(11). PMID: 34693218    Free PMC article.
Next Generation of Cancer Treatments: Chimeric Antigen Receptor T-Cell Therapy and Its Related Toxicities: A Review for Perioperative Physicians.
Germán Echeverry, Gregory W Fischer, Elena Mead.
Anesth Analg, 2019 May 28; 129(2). PMID: 31124841    Free PMC article.
Chimeric antigen receptor-modified human regulatory T cells that constitutively express IL-10 maintain their phenotype and are potently suppressive.
Yasmin R Mohseni, Adeel Saleem, +13 authors, Giovanna Lombardi.
Eur J Immunol, 2021 Jul 29; 51(10). PMID: 34320225    Free PMC article.
Human epidermal growth factor receptor 2 (HER2)-specific chimeric antigen receptor (CAR) for tumor immunotherapy; recent progress.
Hendrik Setia Budi, Firdaus Nuri Ahmad, +6 authors, Faroogh Marofi.
Stem Cell Res Ther, 2022 Jan 31; 13(1). PMID: 35093187    Free PMC article.
Fluctuations in T cell receptor and pMHC interactions regulate T cell activation.
Joseph R Egan, Enas Abu-Shah, +2 authors, Ben D MacArthur.
J R Soc Interface, 2022 Feb 10; 19(187). PMID: 35135295    Free PMC article.
Novel Cellular Therapies for Hepatocellular Carcinoma.
Harriet Roddy, Tim Meyer, Claire Roddie.
Cancers (Basel), 2022 Feb 16; 14(3). PMID: 35158772    Free PMC article.
Genetic Modification of T Cells for the Immunotherapy of Cancer.
Suzanne Quinn, Natasha Lenart, +3 authors, Michael I Nishimura.
Vaccines (Basel), 2022 Mar 27; 10(3). PMID: 35335089    Free PMC article.
c-Met-targeted chimeric antigen receptor T cells inhibit hepatocellular carcinoma cells in vitro and in vivo.
Xiaochen Huang, Jiaojiao Guo, +5 authors, Zhenqing Feng.
J Biomed Res, 2022 Apr 12; 36(1). PMID: 35403606    Free PMC article.